As to our knowledge, the impact of ROS in healthy and cancer tissue is well documented; however, the exact “dose” of ROS generation (and thus Nrf-2 activation) on the effectiveness of anticancer drugs has not been investigated or estimated so far. Here, NFE2L2 is linked to cancer.